Clopidogrel

...disorders involving the body's clotting system. Medications that increase the risk of bleeding, such as aspirin, warfarin (Coumadin), or clopidogrel (Plavix), may also lead to bloody urine. Lastly, cancer anywhere along the urinary tract...

In this article: Kidney stone, Warfarin, Cancer, Back pain, Aspirin, Cystitis, Antibiotics, Nausea, and Vomiting

...- people ). U.S. patents are expiring on many big sellers, including Plavix, the $10 billion heart pill that Sanofi sells with Bristol-Myers Squibb ( BMY - news - people ), and Eloxatin, the company's $2 billion cancer drug. In the U.S., at...

In this article: Sanofi, Bristol-Myers Squibb, Pfizer, Cancer, Breast cancer, Sanofi-Synthelabo, Novartis, and Glaxo

...among patients who are on Coumadin or Plavix. As expected, the use of Coumadin or Plavix led to a significant increase in Grade 3 or 4 bleeding toxicity after radiotherapy. The 4-year risk of serious bleeding toxicity was 16% in...

In this article: Cancer, Coumadin, Plavix, and Cardiovascular disease

...sales, up 6%, and $699 million in Nutritional sales, down 6%. Growth in the pharmaceutical division was driven by strong sales of Plavix at $1,554 million, up 8%, HIV medication Sustiva at $315 million, up 7% and hepatitis B drug Baraclude...

In this article: Bristol-Myers Squibb, Revenue, Plavix, AstraZeneca plc, Bristol, Ipilimumab, LLY, Sanofi-Aventis, and Baraclude

...was partly held back by competition from generics to Sanofi's cancer drug Eloxatin in the United States in August and blood thinner Plavix in Europe. Eloxatin sales fell 44 percent. Sales of irregular heart beat drug Multaq, touted by...

In this article: Sanofi-Aventis, Revenue, Eloxatin, Lantus, European Union, United States, Plavix, and Cancer

...in 2007. Bristol-Myers products on the wholesale price list included the blood thinner Plavix _ its best-selling drug _ along with blood-pressure drug Avapro, cancer treatment Taxol, and the cholesterol-lowering drug Pravachol. The company...

In this article: Bristol-Myers, Justice Department, Massachusetts, Plavix, Abilify, U.S. Attorney, and NEW YORK

...sales by 2015. The sales, Mr. Anderson wrote, would fill a small part of Sanofi's coming losses to generic competition for its blockbusters, which include the blood thinners Plavix and Lovenox, and the cancer drug Taxotere. All of them will...

In this article: Sanofi-Aventis, Atrial fibrillation, Plavix, Amiodarone, Cancer, Taxotere, Stroke, Chest pain, and Cardiovascular disease

...as by contributions from acquisitions. Along with Lantus, group sales benefited from forecast-beating growth for four other key products, including blood thinner Plavix and cancer drug Eloxatin. Those drugs, however, could face early...

In this article: Sanofi-Aventis, Lantus, Cancer, Eloxatin, Plavix, United States, European Medicines Agency, and Insulin

...growth for the market. The company highlighted a return of double-digit sales growth in the slowing U.S. market during the third quarter, thanks to sales of Lantus, Plavix and the cancer drug Taxotere. This made it "among the fastest...

In this article: Sanofi-Aventis, Lantus, U.S., Acomplia, Plavix, IMS Health, Paris, and Adjusted basis